Downer & Company Advises PlasmaSelect AG on Acquisition from curasan AG
BOSTON, September 23, 2003 - Downer & Company, LLC, an international investment banking firm specializing in middle-market corporate acquisitions and divestitures, today announced that the company has advised PlasmaSelect AG on the acquisition of the AIEP pharmaceutical business unit of curasan AG. The purchase price for this transaction, pending shareholder approval, is approximately €14m, based on the value of all inventories at the date of the transfer. Downer & Company served as the sole financial advisor to PlasmaSelect AG.
The AIEP business unit, including current staff, will be integrated into DeltaSelect GmbH, a wholly owned subsidiary of PlasmaSelect AG. DeltaSelect GmbH provides solutions and products for the hospital care market, and, in particular, in-patient, outpatient, and therapy care. The AIEP pharmaceutical division is comprised of injection and intravenous products for Anesthesiology, Intensive-care medicine, Emergency medicine and Pain therapy (AIEP).
The purchase of the assets of the AIEP business unit is in accordance with PlasmaSelect’s overall plan for strategic growth through acquisitions. Professor B. Weidler, chairman of PlasmaSelect AG, said, “The AIEP range of products perfectly complements the present product range of DeltaSelect GmbH, and enables access to further target groups in the hospital segment thus significantly strengthening the market position of DeltaSelect GmbH.” Prof. Weidler continued, “In regards to this mandate, Downer & Company’s creativity concerning possible transaction structures and their negotiation skills were of major importance for the successful completion of this transaction.” This transaction marks the second completed deal for the Downer & Company Frankfurt office since their founding in April of 2003.
curasan AG, based in Kleinostheim, is one of the leading specialists for regenerative medicine in Germany. Although performing solidly, the divestiture of the AIEP pharmaceutical business unit will allow curasan AG to focus resources on their growing Biomaterials division, and, in particular, the synthetic bone reconstruction material, Cerasorb®.About curasan AG
Visit their website at http://www.curasan.de.
Downer & Company, LLC